Drawing for PHANES THERAPEUTICS

USPTO serial 87555473

PHANES THERAPEUTICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
HELLMAN, ELI J
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PHANES THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alex Patel

Alex Patel Patel & Almeida, P. C.16830 Ventura Blvd., Suite 360ENCINO, CA 91436UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Chemical preparations for pharmaceutical or medical purposes, namely, for viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Biological preparations for the treatment of cancer; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Ferments for pharmaceutical purposes; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Medical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Tumor suppressing agents; Clinical medical reagents; Anti-diabetic pharmaceuticals; Anti-cancer preparations; Cellular function activating agents for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 5, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 5, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 19, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 18, 2020EX5GSOU EXTENSION 5 GRANTED—
Aug 18, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 14, 2020EXT5SOU EXTENSION 5 FILED—
Aug 14, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 13, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 11, 2020EX4GSOU EXTENSION 4 GRANTED—
Feb 11, 2020EXT4SOU EXTENSION 4 FILED—
Feb 11, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 7, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 5, 2019EX3GSOU EXTENSION 3 GRANTED—
Aug 5, 2019EXT3SOU EXTENSION 3 FILED—
Aug 5, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 14, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 12, 2019EX2GSOU EXTENSION 2 GRANTED—
Feb 12, 2019EXT2SOU EXTENSION 2 FILED—
Feb 12, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 27, 2018CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Nov 27, 2018COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 17, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 13, 2018EX1GSOU EXTENSION 1 GRANTED—
Jul 13, 2018EXT1SOU EXTENSION 1 FILED—
Jul 13, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 27, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 2, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 2, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 13, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 27, 2017ALIEASSIGNED TO LIE—
Nov 15, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 15, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 14, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 14, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 12, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 3, 2017DOCKASSIGNED TO EXAMINER—
Aug 10, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Aug 9, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 7, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance